Covalon Technologies Ltd. · TSXV:COV
Covalon Technologies — Planet MicroCap Showcase: VEGAS 2023
23 slides from Covalon Technologies's conference presentation, Apr 26, 2023
Slide 1: Planet MicroCap CEO Presentation
TSX-V: COV OTCQX: CVALF Planet MicroCap CEO Presentation April 26th 2023 Brian Pedlar, CEO www.covalon.com helping the most vulnerable patients have a better chance at healing 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements included in this presentation may be considered forward-looking statements. These forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “estimate”, “e
Slide 3: Capitalization Table
TSX-V: COV OTCQX: CVALF ~55% Insider ownership Capitalization Table (in Canadian $) $14mm Share Price (April 24, 2023) ($/share) $2.00 Basic Shares (mm) 24.9 FD ITM Shares (mm) 28.9 Cash FD ITM Market Cap ($ mm) $57.8 Less: Cash (Dec 31, 2022) ($ mm) ($14.1) Plus: Debt Plus: Minority Interest ($ mm)
Slide 4: We aren't just another medical device company
TSX-V: COV We aren’t just OTCQX: CVALF another medical device company… Covalon is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advan
Slide 5: Our Mission
Our Mission Provide innovative and cost-effective healthcare solutions that reduce pain, prevent infection, and promote healing. 5
Slide 6: Covalon is focused on becoming a leading provider of compassionate care solutions
Covalon is focused on becoming a leading provider of compassionate care solutions that help patients heal faster and live better. 6
Slide 7: Fiscal 2023: Strong Path to Financial Growth
Fiscal 2023: Strong Path to Financial Growth Investing in Sales and Marketing initiatives to drive aggressive 2025 Targets: growth in our US Hospital Market • Currently have 70 major hospital customers (> 200 beds) 400 • 3 strong infection prevention products Major Hospitals 6 of the Top 10 Pediatri
Slide 8: Uninsured Hospital-Acquired Infections have increased as much as 63% in ICUs
Uninsured Hospital-Acquired Infections have increased as much as 63% in Intensive Care Units1 1 Weiner-Lastinger, L., Pattabiraman, V., Konnor, R., Patel, P., Wong, E., Xu, S., Dudeck, M. (2022). The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary
Slide 9: Current Standard of Care Products are ineffective
Current “Standard of Care” Products used to combat vascular access and surgical site infections (SSIs) in hospitals in the United States are ineffective1 1 Klevens, R. Monina; Edwards, Jonathan R.; Richards, Chesley L.; Horan, Teresa C.; Gaynes, Robert P; Pollock, Daniel A.; Cardo, Denise M. (2007).
Slide 10: 70% of Hospital-Acquired Infections Are Preventable
70% of Hospital-Acquired Infections Are Preventable $28 Billion 100,000 Treatment Cost1 Annual Deaths1 1.7 Million Annual US Hospital-Acquired Infections1 30% 70% It’s time to give frontline care Preventable Infections providers the right technology 1Klevens, R. Monina; Edwards, Jonathan R.; Richard
Slide 11: Clinicians and Patients are demanding Better, Safer Products
Clinicians and Patients are demanding Better, Safer Products … A Better Standard of Care 11
Slide 12: Many Prestigious Hospitals Choose Covalon
Many Prestigious Hospitals Choose Covalon Some of our Children’s Hospital Customers including 6 of the top 10 in the United States: Some of our Acute Care Hospital Customers in the United States: 12
Slide 13: Strong Distribution Channels
Strong Distribution Channels 2023 Revenue Breakdown > 70 Major Hospitals Direct Sales (> 300 Beds) 6 of 10 Strong Clinical Evidence Top 10 Children’s Hospitals 63% Long-term Care United States & Home Healthcare Distribution Partners 20 International Countries 37% Distributors International ~20 Distr
Slide 14: Balance Sheet with Significant Cash and No Debt
Balance Sheet with Significant Cash and No Debt Key Takeaways Sept. 30, 2022 Dec. 31, 2022 • We ended both Q1 2023 and fiscal 2022 with $14M Cash $14.1M $14.1M cash on the balance sheet Current Assets $27.2M $26.7M Total Assets $30.4M $30.0M • Current assets consists of cash, accounts receivable, in
Slide 15: Quarterly Revenue Growth Last 4 Quarters
Quarterly Revenue Growth Last 4 Quarters Key Takeaways • Strong revenue growth over the past 4 quarters • Forecasting revenue growth for 2023 • United States revenue growth tracking to plan • Middle East revenue continuing to return to expected levels, but still “lumpy” quarter to quarter • Rest of
Slide 16: Our Patented FDA Cleared Product Solutions Focus On
Our Patented FDA Cleared Product Solutions Focus On Infection Prevention • Vascular Access Blood Stream Infections (“BSIs”) • Surgical Site Infections (“SSIs”) • Medical Device-related Infections Advanced Wound Healing • Diabetic chronic wounds • Surgical wounds • Traumatic non-healing wounds • Seri
Slide 17: Better Vascular Access Infection Prevention Solutions
Better Vascular Access Infection Prevention Solutions 25% Antimicrobial Catheter Coating 17
Slide 18: Better Surgical Site Infection Prevention Solutions
Better Surgical Site Infection Prevention Solutions 1818
Slide 19: Protecting patients from the inside out
Protecting patients from the inside out We work with some of the largest Medical Device Organizations to incorporate our infection prevention technologies into their well-known devices, helping clinicians to better protect patients from the inside out. Our Medical Coatings Save Lives 19 19
Slide 20: ColActive Plus
ColActive Plus® For millions of Closes Complex Wounds patients, 6.7M complex Americans are living with a chronic, wounds are non-healing ulcer debilitating. 25% Of people living with Diabetes will experience a diabetic foot ulcer 1 in 4 Families has a family member with a chronic wound $50B The annu
Slide 21: Covalon Delivers
Selected Partners & Distributors Covalon Delivers Regulatory Pathway Expertise Our R&D, Quality, and Regulatory expertise is recognized and sought by global ISO13485: 2016, MDSAP and FDA QSR certified healthcare companies worldwide. Award Winning Products 21
Slide 22: Covalon Has a Strong Growth Platform
Covalon Has a Strong WHY INVEST Growth Platform IN COVALON Financially Strong Core Innovative Product Solutions Massive Growth Potential Business backed by Strong IP Significant cash; no debt Solid clinical evidence backing $8.9 billion infections and chronic Above-market revenue growth patented pro
Slide 23: Covalon Technologies Ltd.
covalon TECHNOLOGIES LTD.
Covalon Technologies — Planet MicroCap Showcase: VEGAS 2023 on 6ix